Afghanistan vs Azerbaijan: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Afghanistan
57.0%
in 2024
Azerbaijan
52.0%
in 2024
Afghanistan rank
136th
Azerbaijan rank
139th
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Afghanistan
- Azerbaijan
How they compare
Afghanistan currently reports 57.0% against 52.0% in Azerbaijan, a difference of 5.0%.
That makes Afghanistan's figure about 1.1 times Azerbaijan's.
The two have swapped places 1 time across 11 shared years of data; in 2014 it was Azerbaijan ahead.
Afghanistan ranks 136th and Azerbaijan ranks 139th of 146 countries.
Across the 2 decades both report, Afghanistan averaged higher in 1 and Azerbaijan in 1.
Head to head by decade
| Decade | Afghanistan | Azerbaijan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 60.5% | 70.0% | 9.5% | Azerbaijan |
| 2020s | 56.4% | 50.6% | 5.8% | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Afghanistan or Azerbaijan?
- Afghanistan, at 57.0% against 52.0% in Azerbaijan as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Afghanistan and Azerbaijan?
- 5.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Azerbaijan?
- 11 years are reported by both, from 2014 to 2024.
- How do Afghanistan and Azerbaijan rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Afghanistan ranks 136th and Azerbaijan ranks 139th of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.